Monica Lazaro has a decade of experience within the academic and CDMO industry as a Scientist, Business Development Professional, Business Manager, and Director of Business and Commercial Operations. She has led teams to create custom technologies that increase revenue and improve the customer experience. These technologies are the foundations for housing analytics and business intelligence tools for optimizing company valuation. Her accomplishments enabled 360-degree company communication providing a “single source of truth” throughout the enterprise. She leveraged multiple technology platforms for the best data and analytics for executive decision-making. Monica plays a key role in preparing investor documents leading to a critical funding milestone.
During Monica’s time as a Scientist, she developed a novel formulation for a clinical drug candidate with multiple bio-pharmaceutical hurdles, such as solubility issues, oxygen degradation, light degradation, and pharmacokinetic challenges. The development of the novel formulation led to Monica being Co-Inventor in five patent submissions. The novel formulation was used for a therapy that is now getting ready to launch commercially in the year 2023 as Fezolinetant. This compound will add $8.9B in revenue by 2025. Fezolinetant is a non-hormonal women’s health therapy to treat vasomotor symptoms.
Ten years from now, Monica’s goal is to continue growing professionally, continuing to make an impact in her industry, taking the lessons she has learned and her expertise, and continuing to apply them to patients.
